ReShape Lifesciences (RSLS) Q3 2025 earnings summary

Executive summary

• Completed a reverse merger with Reshape Lifesciences, resulting in a Nasdaq listing and a new management team as of August 2025.

• Focused on developing immuno-inflammatory and rare disease therapeutics, with lead program VT-1953 advancing toward pivotal trials.

• Commercial pharmaceutical segment in India transitioned to service fee and royalty model with Sun Pharma; major licensing agreement terminated in December 2024.

Financial highlights

• Revenue for the nine months ended September 30, 2025 was $283,163, up from $195,516 year-over-year, primarily from service fees, licensing, and royalties.

• Net loss for the nine months ended September 30, 2025 was $9,198,033, compared to $1,140,904 in the prior year, driven by $7.7 million in one-time transactional and advisory fees related to the merger.

• Cash and cash equivalents at September 30, 2025 were $5.7 million, up from $23,001 at December 31, 2024, due to private placement and ATM financing.

• Operating expenses increased to $9.3 million from $882,543 year-over-year, mainly due to merger-related costs and higher G&A expenses.

Outlook and guidance

• Current cash and financing expected to fund operations for at least 15 months, including initiation of pivotal trial for VT-1953.

• Additional funding will be required to complete clinical trials and advance other pipeline programs.